Literature DB >> 22023526

Comparison of mRNA and lentiviral based transfection of natural killer cells with chimeric antigen receptors recognizing lymphoid antigens.

Laurent Boissel1, Monica Betancur, Weiquan Lu, Winfried S Wels, Teresa Marino, Richard A Van Etten, Hans Klingemann.   

Abstract

Natural killer (NK) cells can be engineered to kill resistant B-lymphoid cell lines and primary B-cell chronic lymphocytic leukemia (B-CLL) cells after transfection with chimeric antigen receptors (CARs) recognizing CD19 or CD20. Here we compared mRNA electroporation with lentiviral vector (LV) transduction for both CARs. Transfection efficiency and cytotoxicity of previously NK-92 resistant CLL cells were significantly higher after mRNA electroporation than after LV transduction. Further cell sorting of LV-transduced NK-92 cells resulted in a highly enriched population of transduced cells with significant target cell lysis. Compared to NK-92 cells, peripheral blood and cord blood cells consistently showed < 10% transfection efficiency with mRNA, while LV transduction varied between 8 and 16% for peripheral blood and 12 and 73% for cord blood. These results suggest that LV should be used to achieve sufficient transgene expression if blood NK cells are considered for CAR transduction. Transfection with mRNA results in clinically relevant levels of transfection only in NK-92 cells.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22023526      PMCID: PMC3491067          DOI: 10.3109/10428194.2011.634048

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  39 in total

Review 1.  Recent advances in lentiviral vector development and applications.

Authors:  Janka Mátrai; Marinee K L Chuah; Thierry VandenDriessche
Journal:  Mol Ther       Date:  2010-01-19       Impact factor: 11.454

2.  Variable contribution of monoclonal antibodies to ADCC in patients with chronic lymphocytic leukemia.

Authors:  James Weitzman; Monica Betancur; Laurent Boissel; Arthur P Rabinowitz; Andreas Klein; Hans Klingemann
Journal:  Leuk Lymphoma       Date:  2009-08

Review 3.  Lentiviral vectors in clinical trials: Current status.

Authors:  Jenice D'Costa; S Gary Mansfield; Laurent M Humeau
Journal:  Curr Opin Mol Ther       Date:  2009-10

Review 4.  Monoclonal antibody therapy of chronic lymphocytic leukaemia.

Authors:  Bruce D Cheson
Journal:  Best Pract Res Clin Haematol       Date:  2010-03       Impact factor: 3.020

Review 5.  Redirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptor.

Authors:  Bipulendu Jena; Gianpietro Dotti; Laurence J N Cooper
Journal:  Blood       Date:  2010-05-03       Impact factor: 22.113

Review 6.  Ofatumumab in the treatment of chronic lymphocytic leukemia.

Authors:  A M Tsimberidou
Journal:  Drugs Today (Barc)       Date:  2010-07       Impact factor: 2.245

Review 7.  Adoptive immunotherapy for cancer: the next generation of gene-engineered immune cells.

Authors:  L J Berry; M Moeller; P K Darcy
Journal:  Tissue Antigens       Date:  2009-10

8.  Engineering antigen-specific primary human NK cells against HER-2 positive carcinomas.

Authors:  Anna Kruschinski; Andreas Moosmann; Isabel Poschke; Håkan Norell; Markus Chmielewski; Barbara Seliger; Rolf Kiessling; Thomas Blankenstein; Hinrich Abken; Jehad Charo
Journal:  Proc Natl Acad Sci U S A       Date:  2008-11-05       Impact factor: 11.205

9.  Expression of chimeric antigen receptors in natural killer cells with a regulatory-compliant non-viral method.

Authors:  L Li; L N Liu; S Feller; C Allen; R Shivakumar; J Fratantoni; L A Wolfraim; H Fujisaki; D Campana; N Chopas; S Dzekunov; M Peshwa
Journal:  Cancer Gene Ther       Date:  2009-09-11       Impact factor: 5.987

10.  Clinical-grade ex vivo-expanded human natural killer cells up-regulate activating receptors and death receptor ligands and have enhanced cytolytic activity against tumor cells.

Authors:  Maria Berg; Andreas Lundqvist; Philip McCoy; Leigh Samsel; Yong Fan; Abdul Tawab; Richard Childs
Journal:  Cytotherapy       Date:  2009       Impact factor: 5.414

View more
  54 in total

Review 1.  An RNA toolbox for cancer immunotherapy.

Authors:  Fernando Pastor; Pedro Berraondo; Iñaki Etxeberria; Josh Frederick; Ugur Sahin; Eli Gilboa; Ignacio Melero
Journal:  Nat Rev Drug Discov       Date:  2018-09-07       Impact factor: 84.694

2.  Charge-altering releasable transporters enable phenotypic manipulation of natural killer cells for cancer immunotherapy.

Authors:  Aaron J Wilk; Nancy Lynn-Benner Weidenbacher; Rosemary Vergara; Ole A W Haabeth; Ronald Levy; Robert M Waymouth; Paul A Wender; Catherine A Blish
Journal:  Blood Adv       Date:  2020-09-08

3.  Efficacy of third-party chimeric antigen receptor modified peripheral blood natural killer cells for adoptive cell therapy of B-cell precursor acute lymphoblastic leukemia.

Authors:  C Quintarelli; S Sivori; S Caruso; S Carlomagno; L Moretta; F Locatelli; M Falco; I Boffa; D Orlando; M Guercio; Z Abbaszadeh; M Sinibaldi; S Di Cecca; A Camera; B Cembrola; A Pitisci; M Andreani; L Vinti; S Gattari; F Del Bufalo; M Algeri; G Li Pira; A Moseley; B De Angelis
Journal:  Leukemia       Date:  2019-11-19       Impact factor: 11.528

4.  Transfection of chimeric anti-CD138 gene enhances natural killer cell activation and killing of multiple myeloma cells.

Authors:  Hua Jiang; Wenhao Zhang; Peipei Shang; Hui Zhang; Weijun Fu; Fei Ye; Tianmei Zeng; Hejing Huang; Xueguang Zhang; Wanping Sun; Daniel Man-Yuen Sze; Qing Yi; Jian Hou
Journal:  Mol Oncol       Date:  2013-12-12       Impact factor: 6.603

Review 5.  Bringing natural killer cells to the clinic: ex vivo manipulation.

Authors:  Richard W Childs; Maria Berg
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2013

Review 6.  Chimeric antigen receptor-engineered natural killer and natural killer T cells for cancer immunotherapy.

Authors:  Dominique Bollino; Tonya J Webb
Journal:  Transl Res       Date:  2017-06-09       Impact factor: 7.012

7.  CRISPR-Cas9 Ribonucleoprotein-Mediated Genomic Editing in Mature Primary Innate Immune Cells.

Authors:  Luke Riggan; Andrew D Hildreth; Marion Rolot; Yung-Yu Wong; William Satyadi; Ryan Sun; Christopher Huerta; Timothy E O'Sullivan
Journal:  Cell Rep       Date:  2020-05-19       Impact factor: 9.423

8.  Genetic and epigenetic modification of human primary NK cells for enhanced antitumor activity.

Authors:  Meisam Naeimi Kararoudi; Brian P Tullius; Nitin Chakravarti; Emily J Pomeroy; Branden S Moriarity; Kathie Beland; Aurelien B L Colamartino; Elie Haddad; Yaya Chu; Mitchell S Cairo; Dean A Lee
Journal:  Semin Hematol       Date:  2020-11-19       Impact factor: 3.851

Review 9.  Chimeric antigen receptor (CAR)-transduced natural killer cells in tumor immunotherapy.

Authors:  Yuan Hu; Zhi-Gang Tian; Cai Zhang
Journal:  Acta Pharmacol Sin       Date:  2017-09-07       Impact factor: 6.150

Review 10.  Chimeric Antigen Receptor T-Cell Therapy for the Community Oncologist.

Authors:  Marcela V Maus; Bruce L Levine
Journal:  Oncologist       Date:  2016-03-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.